Because the treatment of brain metastases involves complex medical knowledge and requires multidisciplinary participation, the treatment of brain metastases in China has not been paid much attention in the past decades. In recent years, with the development and popularization of medical imaging technology and the improvement of the treatment effect of various body tumors, the survival of many patients with body tumors has been significantly improved, and the chance of brain metastasis of tumors has greatly increased, so the incidence of brain metastases has a significant increasing trend. At present, there is no latest epidemiological data about the incidence of brain metastases in China, and some clinical data are mostly quoted from Europe and America. Since I attended the First International Congress of Neurological Malignancies in 2005, I started to pay attention to the research and treatment of brain metastases, and applied the latest international concepts on the treatment of brain metastases to clinical practice, which was recognized by the patients. I would like to borrow the research information about brain metastases in the United States to introduce the progress about the treatment of brain metastases to you. It has been reported that >100,000 new cases of brain metastases occur each year in the United States, which has become the most common brain tumor and more than half of all brain tumors. Brain metastases from tumors occur in approximately 15-30% of patients with somatic cancers. While 15% of patients with brain metastases have no history of cancer, 43-60% of them will have abnormal presentation on chest X-ray (may be primary or metastatic). In 9% of patients with brain metastases, the brain is only the only site of metastasis. Brain metastases occur in only 6% of pediatric tumors. The route of brain metastases is usually hematogenous, while direct intracranial invasion is rare. The source distribution of brain metastases in adults is roughly 44% for lung cancer, 10% for breast cancer, 7% for kidney cancer, 6% for gastrointestinal tumors, 3% for melanoma, and 10% for those of unknown origin. Current treatments for brain metastases include surgery, whole brain radiotherapy, stereotactic radiation therapy and chemotherapy. These treatments are not meant to be applied to all patients, but should be considered according to the source of the tumor, the number, location and size of metastases in the brain, as well as the patient’s general condition and primary disease, and individualized and comprehensive treatments are used for different patients. In addition, regardless of the treatment method used, there are some patient’s own factors that predict a better prognosis: KPS score greater than 70, age less than 65 years, brain is the only site of metastasis without metastasis from other organs, no primary tumor is detected or the primary tumor is controlled, metastasis occurs one year after the primary tumor is diagnosed, low number of brain metastases, and the patient is female, etc.